Introduction
Bispecific antibodies represent one of the most important advances in modern biologics, enabling a single molecule to bind two distinct antigens or epitopes simultaneously. This dual-targeting capability has led to major therapeutic breakthroughs in oncology, immunology, and infectious diseases, and has consequently triggered a rapid increase in global patent filings.
However, patent protection for bispecific antibodies is highly dependent on accurate and fully compliant sequence listings. Because these molecules are structurally complex—often combining multiple heavy and light chains, engineered domains, linkers, and Fc modifications—sequence disclosure must meet strict formal requirements under WIPO ST.26 and corresponding national and regional patent office rules.
Errors in sequence listings can lead to formal objections, delayed prosecution, added cost, or even loss of scope for critical embodiments.
Why Sequence Listings Are Critical for Bispecific Antibody Patents
Unlike small molecules, bispecific antibodies rely on precise amino acid and nucleotide sequences to define their structure and function. Patent offices require these sequences to be disclosed in standardized formats to ensure clarity, reproducibility, and searchability.
A compliant sequence listing ensures that examiners can accurately identify:
- Each antibody chain involved in the bispecific construct
- Variable domains responsible for antigen binding
- CDR regions defining specificity
- Linkers connecting functional domains
- Fc region modifications affecting effector function
- Any engineered mutations introduced for stability or affinity
Without structured sequence disclosure, claims may be considered unclear, insufficiently supported, or not enabled.
Structural Complexity of Bispecific Antibodies
Bispecific antibodies differ from conventional monoclonal antibodies because they integrate two distinct binding specificities into a single molecular architecture.
Common formats include:
- IgG-like bispecific antibodies
- Tandem scFv constructs
- Dual-variable domain immunoglobulins (DVD-Ig)
- CrossMab and knob-into-hole designs
- Single-chain bispecific formats
- Fc-fusion bispecific proteins
Each format introduces unique sequence listing challenges because multiple polypeptide chains must be individually defined and correctly annotated.
WIPO ST.26 Requirements for Antibody Sequence Listings
Since July 1, 2022, most jurisdictions require sequence listings to comply with WIPO Standard ST.26, which uses XML-based formatting for nucleotide and amino acid sequences.
Key ST.26 Principles for Bispecific Antibodies
| Requirement Area | ST.26 Expectation | Practical Impact |
| Sequence Type | Amino acid and nucleotide sequences must be separately defined | Both protein and encoding DNA must be included |
| Identifier System | Unique sequence identifiers (SEQ ID NO) | Each chain must be uniquely labeled |
| Language Format | XML structure required | No free-text sequence submissions |
| Feature Annotation | Structured annotation of regions | CDRs, linkers, Fc domains must be tagged |
| Completeness | Full-length sequences preferred | Partial sequences must be justified |
| Consistency | Must match specification exactly | No discrepancies allowed |
Failure to comply with ST.26 formatting rules may result in formal objections or requirement to resubmit corrected listings.
Essential Sequence Elements in Bispecific Antibody Patents
A robust bispecific antibody sequence listing must clearly define all functional and structural components of the molecule.
1. Heavy and Light Chain Sequences
Each antibody arm typically includes:
- Heavy chain variable region (VH)
- Light chain variable region (VL)
- Constant regions (CH1, CH2, CH3, CL where applicable)
Each chain must be assigned a distinct sequence identifier.
2. CDR Region Annotation
Complementarity-determining regions are critical for antigen binding specificity.
| Region | Function |
| CDR1 | Initial antigen contact |
| CDR2 | Structural binding contribution |
| CDR3 | Primary specificity determinant |
CDRs must be clearly identified using a recognized numbering system such as IMGT or Kabat, and must be consistent across the sequence listing and description.
3. Linkers and Fusion Regions
Bispecific constructs frequently include engineered linkers that connect functional domains.
Common linker types include:
- Flexible glycine-serine repeats
- Protease-cleavable linkers
- Rigid alpha-helical linkers
These linkers must be explicitly included as separate annotated regions in the sequence listing.
4. Fc Region Modifications
Many bispecific antibodies incorporate Fc engineering to alter:
- Effector function (ADCC, CDC)
- Half-life extension
- Reduced immune activation
Common modifications include point mutations, domain swaps, or Fc silencing strategies. All such modifications must be disclosed at sequence level.
5. Nucleotide Sequences
Where DNA constructs are claimed, corresponding nucleotide sequences must be included.
These may include:
- Codon-optimized expression constructs
- Vector-specific inserts
- Synthetic gene assemblies
Sequence consistency between amino acid and nucleotide representations is essential.
Common Compliance Errors in Bispecific Antibody Sequence Listings
Sequence listing deficiencies are among the most frequent issues in biologics patent filings.
| Error Type | Description | Consequence |
| Missing chain sequences | One antibody arm not included | Formal objection |
| Incorrect SEQ ID NO mapping | Mismatch between text and XML | Rejection risk |
| Inconsistent CDR definition | Different numbering systems used | Lack of clarity objection |
| Missing linker annotation | Fusion regions not identified | Support issues |
| Partial sequence omission | Truncated chains without justification | Enablement concerns |
| XML formatting errors | Invalid ST.26 structure | Filing invalidation |
Step-by-Step Approach to Preparing Compliant Listings
A structured preparation process reduces the risk of formal objections and improves prosecution efficiency.
First, all antibody chains should be mapped into a clear structural diagram identifying each variable and constant region. This ensures that no functional component is overlooked during sequence extraction.
Second, each amino acid sequence must be assigned a unique sequence identifier and cross-verified against the patent specification to ensure exact consistency.
Third, all functional regions such as CDRs, linkers, and Fc modifications must be annotated using a standardized system. This annotation should remain consistent across both the sequence listing and written description.
Fourth, corresponding nucleotide sequences must be generated where relevant, ensuring codon alignment and expression construct accuracy.
Finally, the entire listing must be validated in ST.26-compliant XML format before submission to ensure technical correctness and prevent formal filing objections.
Relationship Between Sequence Listings and Claim Scope
In bispecific antibody patents, sequence listings directly influence claim interpretation. Many claims are defined by:
- Sequence identity thresholds
- Specific CDR combinations
- Structural configurations of antibody arms
- Fc engineering modifications
- Binding specificity to two targets
If sequence listings are incomplete or inconsistent, claim support under sufficiency and written description requirements may be challenged during examination or opposition proceedings.
Best Practices for High-Quality Sequence Listings
A strong sequence listing strategy ensures both compliance and enforceability. High-quality filings typically involve:
Careful harmonization between claims, specification, and sequence listing to ensure that every disclosed sequence is fully supported by the written description. Early integration of sequence listing preparation into the drafting process rather than treating it as a final administrative step. Use of consistent CDR numbering conventions throughout the application. Independent technical verification of all sequences before ST.26 conversion. And final validation using automated and manual review to eliminate XML or annotation errors.
Conclusion
Bispecific antibody patents require a higher level of precision in sequence disclosure than most other biologic inventions due to their structural complexity and multi-domain architecture. Compliance with WIPO ST.26 is not merely a formal requirement but a critical factor in securing strong, enforceable patent rights.
A well-prepared sequence listing ensures that every functional element of the bispecific antibody is clearly defined, consistently represented, and legally supported. In an increasingly competitive biologics landscape, careful sequence listing preparation is essential for reducing prosecution risk and maximizing the value of intellectual property protection.